Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 244

1.

Pathogenesis of Fungal Infections in Cystic Fibrosis.

Williams C, Ranjendran R, Ramage G.

Curr Fungal Infect Rep. 2016;10(4):163-169. doi: 10.1007/s12281-016-0268-z. Review.

2.

Regulation of Pseudomonas aeruginosa Virulence by Distinct Iron Sources.

Reinhart AA, Oglesby-Sherrouse AG.

Genes (Basel). 2016 Dec 14;7(12). pii: E126. Review.

3.

Ceftolozane/tazobactam and ceftazidime/avibactam for the treatment of complicated intra-abdominal infections.

Goodlet KJ, Nicolau DP, Nailor MD.

Ther Clin Risk Manag. 2016 Dec 1;12:1811-1826. Review.

4.

Bronchiectasis in the Last Five Years: New Developments.

Khoo JK, Venning V, Wong C, Jayaram L.

J Clin Med. 2016 Dec 8;5(12). pii: E115. Review.

5.
6.

Modular Approach to Select Bacteriophages Targeting <i>Pseudomonas aeruginosa</i> for Their Application to Children Suffering With Cystic Fibrosis.

Krylov V, Shaburova O, Pleteneva E, Bourkaltseva M, Krylov S, Kaplan A, Chesnokova E, Kulakov L, Magill D, Polygach O.

Front Microbiol. 2016 Oct 13;7:1631. Review.

7.

Extracellular Bacterial Proteases in Chronic Wounds: A Potential Therapeutic Target?

Suleman L.

Adv Wound Care (New Rochelle). 2016 Oct 1;5(10):455-463. Review.

8.

Inhalable Antimicrobials for Treatment of Bacterial Biofilm-Associated Sinusitis in Cystic Fibrosis Patients: Challenges and Drug Delivery Approaches.

Kłodzińska SN, Priemel PA, Rades T, Mørck Nielsen H.

Int J Mol Sci. 2016 Oct 9;17(10). pii: E1688. Review.

10.

PCR-based assay for the rapid and precise distinction of Pseudomonas aeruginosa from other Pseudomonas species recovered from burns patients.

Gholami A, Majidpour A, Talebi-Taher M, Boustanshenas M, Adabi M.

J Prev Med Hyg. 2016;57(2):E81-5. Review.

11.
12.

Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis.

Wilson R, Aksamit T, Aliberti S, De Soyza A, Elborn JS, Goeminne P, Hill AT, Menendez R, Polverino E.

Respir Med. 2016 Aug;117:179-89. doi: 10.1016/j.rmed.2016.06.007. Review.

13.

Toxin-Antitoxin Systems in Clinical Pathogens.

Fernández-García L, Blasco L, Lopez M, Bou G, García-Contreras R, Wood T, Tomas M.

Toxins (Basel). 2016 Jul 20;8(7). pii: E227. doi: 10.3390/toxins8070227. Review.

14.

The T6SSs of Pseudomonas aeruginosa Strain PAO1 and Their Effectors: Beyond Bacterial-Cell Targeting.

Sana TG, Berni B, Bleves S.

Front Cell Infect Microbiol. 2016 Jun 9;6:61. doi: 10.3389/fcimb.2016.00061. Review.

15.

[Colistin in the post-antibiotic era].

Aguayo A, Mella S, Riedel G, Bello H, Domínguez M, González-Rocha G.

Rev Chilena Infectol. 2016 Apr;33(2):166-76. doi: 10.4067/S0716-10182016000200006. Review. Spanish.

16.

Critical evaluation of ceftolozane-tazobactam for complicated urinary tract and intra-abdominal infections.

Giancola SE, Mahoney MV, Bias TE, Hirsch EB.

Ther Clin Risk Manag. 2016 May 19;12:787-97. doi: 10.2147/TCRM.S83844. Review.

17.

Mechanisms of Antimicrobial Resistance in ESKAPE Pathogens.

Santajit S, Indrawattana N.

Biomed Res Int. 2016;2016:2475067. doi: 10.1155/2016/2475067. Review.

18.

Biofilms and Cyclic di-GMP (c-di-GMP) Signaling: Lessons from Pseudomonas aeruginosa and Other Bacteria.

Valentini M, Filloux A.

J Biol Chem. 2016 Jun 10;291(24):12547-55. doi: 10.1074/jbc.R115.711507. Review.

19.

Clinical Usefulness of Arbekacin.

Lee JH, Lee CS.

Infect Chemother. 2016 Mar;48(1):1-11. doi: 10.3947/ic.2016.48.1.1. Review.

20.

Mortality attributable to carbapenem-resistant Pseudomonas aeruginosa bacteremia: a meta-analysis of cohort studies.

Zhang Y, Chen XL, Huang AW, Liu SL, Liu WJ, Zhang N, Lu XZ.

Emerg Microbes Infect. 2016 Mar 23;5:e27. doi: 10.1038/emi.2016.22. Review.

Items per page

Supplemental Content

Loading ...
Support Center